Lilly Reports Results of Dual GIP and GIP-1 Receptor Agonist with Reduction in HbA1c and Body Weight

 Lilly Reports Results of Dual GIP and GIP-1 Receptor Agonist with Reduction in HbA1c and Body Weight

Lilly Reports Results of Dual GIP and GIP-1 Receptor Agonist with Reduction in HbA1c and Body Weight

Shots:

  • The P-II study involves assessing of four doses of GIP/GLP-1 RA, LY3298176 (1 mg, 5 mg, 10 mg, 15 mg) vs PBO and dulaglutide 1.5 mg in 200 patients with Type 2 Diabetes for 26 weeks
  • P-II study results (GIP/GLP-1 RA (5/10/15 mg) vs dulaglutide and PBO): HbA1c reduction (-1.6% @5 mg, -2.0% @10 mg, and -2.4% @15 mg; vs -1.1% @1.5 mg vs 0.1%): HbA1c target (69.1% @5 mg, 90.0% @10 mg, and 77.4% @15 mg; vs 51.9% @1.5mg); Weight loss (-4.8 kg @5 mg, -8.7 kg@10 mg and -11.3 kg @15 mg vs -2.7 kg @1.5mg vs 0.4 kg)
  • Lilly plans to initiate P-III SURPASS program trial for assessing safety and efficacy of GIP/GLP-1 RA for Type 2 Diabetes and is expected to begin in no later than early 2019 with its closure in 2021

Click here to read full press release/ article | Ref: Eli Lilly | Image: Pharmvestnik

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post